EMCURE LAUNCHES DIABETES DIVISION
 

CRIANTE - DIABETES … A WAY FORWARD

As living conditions improve in India, we are increasingly following western dietary habits, adopting sedentary life style, and getting more prone to stress related disorders. This has resulted in an unprecedented rise of diabetes in India.Indians tend to be diabetic at a relatively younger age of 45 years and it will not be an exaggeration to state that India is now regarded as the world diabetic capital.

The Antidiabetic Market is the 2nd largest Therapeutic Segment with total of 2222 Crs Value growing at 22%. Total Oral Antidiabetic Market is of 1600 Crs Value & is growing at 26%.

Emcure takes a giant leap by venturing into diabetic segment by launching Criante, a new diabetic care division. We will be introducing molecules viz. Metformin, Glimepiride, Gliclazide, Voglibose, Pioglitazone, Acarbose, Pregaboline, Olmesartan, Orlistat & Multivitamin -multiminerals Preparation.

The goal is to provide the best quality drugs and also to take up diabetes as a Corporate Social Responsibility.